Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy

Debora Martorelli, Karim Houali, Laura Caggiari, Emanuela Vaccher, Luigi Barzan, Giovanni Franchin, Annunziata Gloghini, Alessandro Pavan, Alessandro Da Ponte, Rosa Maria Tedeschi, Valli De Re, Antonino Carbone, Tadamasa Ooka, Paolo De Paoli, Riccardo Dolcetti

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Immunotherapy approaches targeting Epstein-Barr virus (EBV)-encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized the immunogenicity of the EBV-encoded BARF1 oncogene with the aim to assess whether this protein could constitute a new target antigen for immunotherapy in this setting. Spontaneous CD4+ and CD8+ T cell responses specific for the recombinant p29 BARF1 protein were detected by IFNγ-ELISPOT in both EBV-seropositive donors and UNPC patients, but not in EBV-seronegative individuals. Using immunoinformatic prediction tools, we have selected 5 different candidate BARF1 T cell epitopes presented by HLA-A*0201. Although only one of these peptides was able to bind HLA-A2 with low affinity in the T2 stabilization assay, all 5 BARF1 nonamers readily elicited specific CD8+ T cell responses in EBV-seropositive HLA-A*0201+ donors and UNPC patients. Notably, the magnitude of CD8+ T cell responses to the whole BARF1 protein and derived A*0201 peptides was significantly higher in UNPC patients than in healthy donors. Moreover, cytotoxic T lymphocytes specific for the p2-10, p23-31, or p49-57 BARF1 peptides were easily obtained from HLA-A*0201+ donors. These cultures were not only able to lyse autologous targets loaded with the antigenic peptide, but also recognized tumor cells endogenously expressing BARF1 in an antigen-specific and HLA-A2-restricted manner. These findings, indicate that BARF1 is a particularly attractive antigen with immunogenic properties in most UNPC patients and provide valuable information to develop new strategies to improve the efficacy of EBV-targeting immunotherapy of UNPC patients.

Original languageEnglish
Pages (from-to)1100-1107
Number of pages8
JournalInternational Journal of Cancer
Volume123
Issue number5
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

Human Herpesvirus 4
Immunotherapy
Carcinoma
T-Lymphocytes
Peptides
Tissue Donors
HLA-A2 Antigen
Antigens
Enzyme-Linked Immunospot Assay
Proteins
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Oncogenes
Human herpesvirus 4 BARF1 protein
Nasopharyngeal carcinoma
HLA-A*02:01 antigen
Neoplasms

Keywords

  • BARF1
  • Epstein-barr virus
  • Immunotherapy
  • Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma : Bases for improved immunotherapy. / Martorelli, Debora; Houali, Karim; Caggiari, Laura; Vaccher, Emanuela; Barzan, Luigi; Franchin, Giovanni; Gloghini, Annunziata; Pavan, Alessandro; Da Ponte, Alessandro; Tedeschi, Rosa Maria; De Re, Valli; Carbone, Antonino; Ooka, Tadamasa; De Paoli, Paolo; Dolcetti, Riccardo.

In: International Journal of Cancer, Vol. 123, No. 5, 01.09.2008, p. 1100-1107.

Research output: Contribution to journalArticle

Martorelli, Debora ; Houali, Karim ; Caggiari, Laura ; Vaccher, Emanuela ; Barzan, Luigi ; Franchin, Giovanni ; Gloghini, Annunziata ; Pavan, Alessandro ; Da Ponte, Alessandro ; Tedeschi, Rosa Maria ; De Re, Valli ; Carbone, Antonino ; Ooka, Tadamasa ; De Paoli, Paolo ; Dolcetti, Riccardo. / Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma : Bases for improved immunotherapy. In: International Journal of Cancer. 2008 ; Vol. 123, No. 5. pp. 1100-1107.
@article{e966f269f87a42dc9644db2890f1b24c,
title = "Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy",
abstract = "Immunotherapy approaches targeting Epstein-Barr virus (EBV)-encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized the immunogenicity of the EBV-encoded BARF1 oncogene with the aim to assess whether this protein could constitute a new target antigen for immunotherapy in this setting. Spontaneous CD4+ and CD8+ T cell responses specific for the recombinant p29 BARF1 protein were detected by IFNγ-ELISPOT in both EBV-seropositive donors and UNPC patients, but not in EBV-seronegative individuals. Using immunoinformatic prediction tools, we have selected 5 different candidate BARF1 T cell epitopes presented by HLA-A*0201. Although only one of these peptides was able to bind HLA-A2 with low affinity in the T2 stabilization assay, all 5 BARF1 nonamers readily elicited specific CD8+ T cell responses in EBV-seropositive HLA-A*0201+ donors and UNPC patients. Notably, the magnitude of CD8+ T cell responses to the whole BARF1 protein and derived A*0201 peptides was significantly higher in UNPC patients than in healthy donors. Moreover, cytotoxic T lymphocytes specific for the p2-10, p23-31, or p49-57 BARF1 peptides were easily obtained from HLA-A*0201+ donors. These cultures were not only able to lyse autologous targets loaded with the antigenic peptide, but also recognized tumor cells endogenously expressing BARF1 in an antigen-specific and HLA-A2-restricted manner. These findings, indicate that BARF1 is a particularly attractive antigen with immunogenic properties in most UNPC patients and provide valuable information to develop new strategies to improve the efficacy of EBV-targeting immunotherapy of UNPC patients.",
keywords = "BARF1, Epstein-barr virus, Immunotherapy, Nasopharyngeal carcinoma",
author = "Debora Martorelli and Karim Houali and Laura Caggiari and Emanuela Vaccher and Luigi Barzan and Giovanni Franchin and Annunziata Gloghini and Alessandro Pavan and {Da Ponte}, Alessandro and Tedeschi, {Rosa Maria} and {De Re}, Valli and Antonino Carbone and Tadamasa Ooka and {De Paoli}, Paolo and Riccardo Dolcetti",
year = "2008",
month = "9",
day = "1",
doi = "10.1002/ijc.23621",
language = "English",
volume = "123",
pages = "1100--1107",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma

T2 - Bases for improved immunotherapy

AU - Martorelli, Debora

AU - Houali, Karim

AU - Caggiari, Laura

AU - Vaccher, Emanuela

AU - Barzan, Luigi

AU - Franchin, Giovanni

AU - Gloghini, Annunziata

AU - Pavan, Alessandro

AU - Da Ponte, Alessandro

AU - Tedeschi, Rosa Maria

AU - De Re, Valli

AU - Carbone, Antonino

AU - Ooka, Tadamasa

AU - De Paoli, Paolo

AU - Dolcetti, Riccardo

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Immunotherapy approaches targeting Epstein-Barr virus (EBV)-encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized the immunogenicity of the EBV-encoded BARF1 oncogene with the aim to assess whether this protein could constitute a new target antigen for immunotherapy in this setting. Spontaneous CD4+ and CD8+ T cell responses specific for the recombinant p29 BARF1 protein were detected by IFNγ-ELISPOT in both EBV-seropositive donors and UNPC patients, but not in EBV-seronegative individuals. Using immunoinformatic prediction tools, we have selected 5 different candidate BARF1 T cell epitopes presented by HLA-A*0201. Although only one of these peptides was able to bind HLA-A2 with low affinity in the T2 stabilization assay, all 5 BARF1 nonamers readily elicited specific CD8+ T cell responses in EBV-seropositive HLA-A*0201+ donors and UNPC patients. Notably, the magnitude of CD8+ T cell responses to the whole BARF1 protein and derived A*0201 peptides was significantly higher in UNPC patients than in healthy donors. Moreover, cytotoxic T lymphocytes specific for the p2-10, p23-31, or p49-57 BARF1 peptides were easily obtained from HLA-A*0201+ donors. These cultures were not only able to lyse autologous targets loaded with the antigenic peptide, but also recognized tumor cells endogenously expressing BARF1 in an antigen-specific and HLA-A2-restricted manner. These findings, indicate that BARF1 is a particularly attractive antigen with immunogenic properties in most UNPC patients and provide valuable information to develop new strategies to improve the efficacy of EBV-targeting immunotherapy of UNPC patients.

AB - Immunotherapy approaches targeting Epstein-Barr virus (EBV)-encoded antigens induce objective clinical responses only in a fraction of patients with undifferentiated nasopharyngeal carcinoma (UNPC). In the present study, we have characterized the immunogenicity of the EBV-encoded BARF1 oncogene with the aim to assess whether this protein could constitute a new target antigen for immunotherapy in this setting. Spontaneous CD4+ and CD8+ T cell responses specific for the recombinant p29 BARF1 protein were detected by IFNγ-ELISPOT in both EBV-seropositive donors and UNPC patients, but not in EBV-seronegative individuals. Using immunoinformatic prediction tools, we have selected 5 different candidate BARF1 T cell epitopes presented by HLA-A*0201. Although only one of these peptides was able to bind HLA-A2 with low affinity in the T2 stabilization assay, all 5 BARF1 nonamers readily elicited specific CD8+ T cell responses in EBV-seropositive HLA-A*0201+ donors and UNPC patients. Notably, the magnitude of CD8+ T cell responses to the whole BARF1 protein and derived A*0201 peptides was significantly higher in UNPC patients than in healthy donors. Moreover, cytotoxic T lymphocytes specific for the p2-10, p23-31, or p49-57 BARF1 peptides were easily obtained from HLA-A*0201+ donors. These cultures were not only able to lyse autologous targets loaded with the antigenic peptide, but also recognized tumor cells endogenously expressing BARF1 in an antigen-specific and HLA-A2-restricted manner. These findings, indicate that BARF1 is a particularly attractive antigen with immunogenic properties in most UNPC patients and provide valuable information to develop new strategies to improve the efficacy of EBV-targeting immunotherapy of UNPC patients.

KW - BARF1

KW - Epstein-barr virus

KW - Immunotherapy

KW - Nasopharyngeal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=47249092365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249092365&partnerID=8YFLogxK

U2 - 10.1002/ijc.23621

DO - 10.1002/ijc.23621

M3 - Article

C2 - 18546263

AN - SCOPUS:47249092365

VL - 123

SP - 1100

EP - 1107

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -